Repligen Corporation

NasdaqGS:RGEN 株式レポート

時価総額:US$7.0b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Repligen 過去の業績

過去 基準チェック /16

Repligenは、平均年間25.4%の収益成長を遂げていますが、 Life Sciences業界の収益は、年間 成長しています。収益は、平均年間16.8% 23.3%収益成長率で 成長しています。 Repligenの自己資本利益率は0.8%であり、純利益率は2.4%です。

主要情報

25.4%

収益成長率

23.5%

EPS成長率

Life Sciences 業界の成長21.5%
収益成長率23.3%
株主資本利益率0.8%
ネット・マージン2.4%
前回の決算情報31 Mar 2024

最近の業績更新

Recent updates

Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Jun 14
Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Jun 10
Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Repligen Stock: Still Quite Overvalued

May 30

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

May 03
Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Apr 30
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Apr 15
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Feb 13
At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Jan 08
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

Dec 19
Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Nov 01
What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Oct 17
Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Sep 29
Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade

Aug 09
Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade

Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?

Jul 17
Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?

Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?

Jul 03
Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?

With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case

Jun 19
With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case

Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)

May 23
Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly

Apr 11
Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly

Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?

Mar 28
Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?

We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease

Mar 08
We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Feb 20
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly

Jan 10
Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly

Should You Think About Buying Repligen Corporation (NASDAQ:RGEN) Now?

Dec 28
Should You Think About Buying Repligen Corporation (NASDAQ:RGEN) Now?

Is Repligen (NASDAQ:RGEN) A Risky Investment?

Oct 03
Is Repligen (NASDAQ:RGEN) A Risky Investment?

収支内訳

Repligen の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:RGEN 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 246071522242
31 Dec 236394221643
30 Sep 2367011621044
30 Jun 2372913820943
31 Mar 2377816821844
31 Dec 2280218621644
30 Sep 2280116621042
30 Jun 2277915920441
31 Mar 2273414619439
31 Dec 2167112818434
30 Sep 2159311916432
30 Jun 2150910014527
31 Mar 214338012723
31 Dec 203666011620
30 Sep 203274411219
30 Jun 203023110720
31 Mar 202862310021
31 Dec 19270219619
30 Sep 19253238117
30 Jun 19233277216
31 Mar 19210216916
31 Dec 18194176616
30 Sep 18184236416
30 Jun 18171236414
31 Mar 18155295810
31 Dec 1714128529
30 Sep 1712521438
30 Jun 1711318348
31 Mar 1711013318
31 Dec 1610512317
30 Sep 161007277
30 Jun 16968286
31 Mar 16888256
31 Dec 15849256
30 Sep 15789236
30 Jun 15748216
31 Mar 15687196
31 Dec 14648166
30 Sep 146312156
30 Jun 146616145
31 Mar 146818136
31 Dec 136816137
30 Sep 137222138

質の高い収益: RGENには$13.1M } という大きな 一回限りの 損失があり、過去 12 か月の財務実績が31st March, 2024に影響を及ぼしています。

利益率の向上: RGENの現在の純利益率 (2.4%)は、昨年(21.6%)よりも低くなっています。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: RGENの収益は過去 5 年間で年間25.4%増加しました。

成長の加速: RGENは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: RGENは過去 1 年間で収益成長率がマイナス ( -91.2% ) となったため、 Life Sciences業界平均 ( -6.5% ) と比較することが困難です。


株主資本利益率

高いROE: RGENの 自己資本利益率 ( 0.8% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘